|
|
 |
|
Viewing report
|
|
|
|
Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline
GBI Research, Sep 2011, Pages: 114
“Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global coagulation disorders market. The report analyzes the markets for coagulation disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Market size, annual cost of therapy and treatment usage patterns are forecast until 2016 for the key geographies, as well as the leading therapeutic segments which includes hemophilia A, hemophilia B and von Willebrand Disease. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global coagulation disorders market.
Scope
The scope of this report includes:
- Annualized market data for the coagulation disorders market from 2002 to 2010, forecast forward to 2017.
- Analysis of the leading therapeutic segments, including hemophilia A, hemophilia B, and von Willebrand’s disease (vWD).
- Analysis of the coagulation disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the coagulation disorders market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Baxter International Inc, Bayer AG, Novo Nordisk A/S, Pfizer Inc and CSL Behring LLC.
- Key M&A activities and licensing agreements that have taken place between 2004 and 2010 in the global coagulation disorders market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with higher efficiency and better safety.
- Develop strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
|
|
|
|
